This engaging symposium at the 2025 ESMO Gynaecological Cancers Congress explored treatment strategies in advanced endometrial cancer (EC), focusing on the key role of immunotherapy in combination with targeted treatment options such as lenvatinib. Read now to deep dive into the clinical evidence supporting these evolving treatment approaches and gain real-world insights into optimal patient selection and adverse event management.
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Latest articles
All articles
